Office of Quality and Patient Safety, New York State Department of Health, Albany (Egglefield, Cogan); School of Public Health, State University of New York at Albany, Rensselaer (Cogan, Leckman-Westin); New York State Office of Mental Health, Albany (Leckman-Westin) and New York (Finnerty); New York University Langone Health, New York (Finnerty).
Psychiatr Serv. 2020 Mar 1;71(3):236-242. doi: 10.1176/appi.ps.201800505. Epub 2019 Nov 20.
This cross-sectional study examined the relationship between antipsychotic medication adherence and preventable diabetes-related hospitalizations for individuals with diabetes and schizophrenia.
Hospitalizations related to diabetes, an ambulatory care sensitive condition, were assessed among Medicaid recipients in New York State with comorbid diabetes and schizophrenia (N=14,365) for three levels of antipsychotic medication adherence: very low to no engagement (two or fewer prescriptions or none in first 6 months), moderate to low adherence, and adherent (proportion of days covered ≥80%).
Rates of preventable diabetes hospitalization were highest among individuals with very low to no engagement in antipsychotic treatment (4.7%), followed by those with moderate to low adherence (3.3%). Diabetes hospitalizations among adherent individuals were comparable with those of the total diabetes population (both 2.0%). The odds of a preventable diabetes hospitalization were significantly higher among individuals with very low to no engagement in antipsychotic treatment (adjusted odds ratio [AOR]=2.42) and among those with moderate to low adherence (AOR=1.57) than among adherent individuals. Black individuals were also at increased risk of a preventable diabetes hospitalization after the analyses adjusted for antipsychotic adherence and other variables (AOR=1.38).
This study indicates a relationship between antipsychotic adherence and improved diabetes outcomes among individuals with schizophrenia. Engagement in mental health treatment may be a critical path toward improving health disparities for individuals with schizophrenia. Individuals with very low to no engagement were a particularly vulnerable group, and the exclusion of persons with less than two prescriptions from research and quality measures should be revisited.
本横断面研究旨在探讨精神分裂症合并糖尿病患者抗精神病药物依从性与可预防的糖尿病相关住院治疗之间的关系。
在纽约州接受医疗补助的合并糖尿病和精神分裂症的患者中(N=14365),评估了与糖尿病相关的住院治疗,糖尿病是一种门诊治疗敏感的疾病,评估了三种抗精神病药物依从性水平:非常低或无用药依从性(前 6 个月内开了 2 种或更少的处方或无处方)、中低用药依从性和用药依从性(覆盖天数比例≥80%)。
在抗精神病药物治疗无或极低依从的患者中(4.7%),可预防的糖尿病住院率最高,其次是中低依从的患者(3.3%)。在依从性患者中,糖尿病住院率与糖尿病总人群相当(均为 2.0%)。与用药依从性患者相比,抗精神病药物治疗无或极低依从的患者(调整后的优势比 [AOR]=2.42)和中低依从的患者(AOR=1.57)发生可预防的糖尿病住院治疗的可能性显著更高。在调整了抗精神病药物依从性和其他变量后,黑人患者发生可预防的糖尿病住院治疗的风险也增加(AOR=1.38)。
本研究表明,精神分裂症患者的抗精神病药物依从性与改善糖尿病结局之间存在关联。参与心理健康治疗可能是改善精神分裂症患者健康差异的关键途径。无或极低依从性的患者是一个特别脆弱的群体,应重新审视将少于 2 种处方的患者排除在研究和质量措施之外的做法。